ISRCTN49376288 : Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI). Six-week treatment plus optional continuation for 18 weeks.
- Overall trial status
- Recruitment status
- No longer recruiting
Mental and Behavioural Disorders